CTL019 Out of Specification MAP for ALL or DLBCL Patients

• Conditions: Diffuse Large B-cell Lymphoma (DLBCL); Acute Lymphoblastic Leukemia (ALL)

• Registration Number: NCT03601442
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.

Detailed Description

The purpose of this Managed Access Program (MAP) Treatment Plan is to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release where no overwhelming safety concerns has been identified for manufacture and release of the out of specification product.

Study Timeline

• Study First Submitted: 2018-07-16
• Study First Submitted QC: 2018-07-16
• Study First Posted: 2018-07-26
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-25
• Last Update Posted: 2024-10-28

Recruitment & Eligibility

• Status: AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria:

1. Patients must be treated at a healthcare facility that has been certified /qualified by Novartis to dispense and administer tisagenlecleucel in line with the tisagenlecleucel Risk Evaluation and Mitigation Strategy (REMS) in the United States (US) or the local Risk Management Plan (RMP).

   • Note that tisagenlecleucel treatment should be initiated under the direction of and supervised by a HCP experienced in the treatment of hematological malignancies and trained for administration and management of patients treated with tisagenlecleucel. The healthcare facility must have tocilizumab for use in the event of cytokine release syndrome and emergency equipment per patient prior to infusion on site and ensure timely access to additional doses of tocilizumab; for detailed requirements refer to the approved local label.

2. Patients must be prescribed tisagenlecleucel in line with the locally approved indications (for the precise indication statements see approved local product label). These may include:

   • pediatric and young adult patients up to and (including) 25 years of age with refractory/relapsed (r/r) acute lymphoblastic leukemia (B-ALL)
   • adult patients with r/r diffuse large B-cell lymphoma (DLBCL)

3. Informed consent must be obtained prior to treatment

4. The incoming apheresis material and/or the final manufactured product is out of specification due to failure to meet acceptance or release specifications

Exclusion Criteria

Patients eligible for this Treatment Plan must not meet any of the following criteria:

1. Contraindications as per the approved local label or the IB.

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (143)

Banner MDACC; 🇺🇸 Gilbert, Arizona, United States

University of Arizona Cancer Center; 🇺🇸 Phoenix, Arizona, United States

Banner University of Arizona Medical Center; 🇺🇸 Phoenix, Arizona, United States

Phoenix Children's Hospital; 🇺🇸 Phoenix, Arizona, United States

Phoenix Childrens Hospital; 🇺🇸 Phoenix, Arizona, United States

Banner Uni Medical Center Tucson; 🇺🇸 Tucson, Arizona, United States

City of Hope National Medical Center Hematology&HematCellTransplant; 🇺🇸 Duarte, California, United States

City of Hope; 🇺🇸 Duarte, California, United States

Children's Hospital Los Angeles CRFB002H2301; 🇺🇸 Los Angeles, California, United States

Children's Hospital Los Angeles; 🇺🇸 Los Angeles, California, United States

Scroll for more (133 remaining)